144 related articles for article (PubMed ID: 20714805)
1. From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy.
Polonelli L; Magliani W; Ciociola T; Giovati L; Conti S
Antonie Van Leeuwenhoek; 2011 Jan; 99(1):35-41. PubMed ID: 20714805
[TBL] [Abstract][Full Text] [Related]
2. From yeast killer toxins to antibiobodies and beyond.
Magliani W; Conti S; Travassos LR; Polonelli L
FEMS Microbiol Lett; 2008 Nov; 288(1):1-8. PubMed ID: 18785931
[TBL] [Abstract][Full Text] [Related]
3. Killer anti-idiotypes in the control of fungal infections.
Magliani W; Conti S; Arseni S; Frazzi R; Salati A; Polonelli L
Curr Opin Investig Drugs; 2001 Apr; 2(4):477-9. PubMed ID: 11566002
[TBL] [Abstract][Full Text] [Related]
4. Protective antifungal yeast killer toxin-like antibodies.
Magliani W; Conti S; Frazzi R; Ravanetti L; Maffei DL; Polonelli L
Curr Mol Med; 2005 Jun; 5(4):443-52. PubMed ID: 15978000
[TBL] [Abstract][Full Text] [Related]
5. A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication.
Casoli C; Pilotti E; Perno CF; Balestra E; Polverini E; Cassone A; Conti S; Magliani W; Polonelli L
AIDS; 2006 Apr; 20(7):975-80. PubMed ID: 16603848
[TBL] [Abstract][Full Text] [Related]
6. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy.
Magliani W; Conti S; Salati A; Arseni S; Ravanetti L; Frazzi R; Polonelli L
Curr Med Chem; 2004 Jul; 11(13):1793-800. PubMed ID: 15279582
[TBL] [Abstract][Full Text] [Related]
7. In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide.
Fiori PL; Mattana A; Dessì D; Conti S; Magliani W; Polonelli L
J Antimicrob Chemother; 2006 May; 57(5):891-8. PubMed ID: 16507561
[TBL] [Abstract][Full Text] [Related]
8. Human natural yeast killer toxin-like candidacidal antibodies.
Polonelli L; De Bernadis F; Conti S; Boccanera M; Magliani W; Gerloni M; Cantelli C; Cassone A
J Immunol; 1996 Mar; 156(5):1880-5. PubMed ID: 8596040
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.
Conti G; Magliani W; Conti S; Nencioni L; Sgarbanti R; Palamara AT; Polonelli L
Antimicrob Agents Chemother; 2008 Dec; 52(12):4331-7. PubMed ID: 18824612
[TBL] [Abstract][Full Text] [Related]
10. Yeast killer toxin-like candidacidal Ab6 antibodies elicited through the manipulation of the idiotypic cascade.
Polonelli L; Beninati C; Teti G; Felici F; Ciociola T; Giovati L; Sperindè M; Lo Passo C; Pernice I; Domina M; Arigò M; Papasergi S; Mancuso G; Conti S; Magliani W
PLoS One; 2014; 9(8):e105727. PubMed ID: 25162681
[TBL] [Abstract][Full Text] [Related]
11. Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis.
Séguy N; Polonelli L; Dei-Cas E; Cailliez JC
FEMS Immunol Med Microbiol; 1998 Sep; 22(1-2):145-9. PubMed ID: 9792073
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis.
Travassos LR; Silva LS; Rodrigues EG; Conti S; Salati A; Magliani W; Polonelli L
J Antimicrob Chemother; 2004 Nov; 54(5):956-8. PubMed ID: 15448128
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes.
Magliani W; Conti S; Salati A; Vaccari S; Ravanetti L; Maffei DL; Polonelli L
FEMS Yeast Res; 2004 Oct; 5(1):11-8. PubMed ID: 15381118
[TBL] [Abstract][Full Text] [Related]
14. Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs.
Magliani W; Conti S; Ciociola T; Giovati L; Zanello PP; Pertinhez T; Spisni A; Polonelli L
Future Med Chem; 2011 Jul; 3(9):1209-31. PubMed ID: 21806382
[TBL] [Abstract][Full Text] [Related]
15. Peptide derived from anti-idiotypic single-chain antibody is a potent antifungal agent compared to its parent fungicide HM-1 killer toxin peptide.
Kabir ME; Karim N; Krishnaswamy S; Selvakumar D; Miyamoto M; Furuichi Y; Komiyama T
Appl Microbiol Biotechnol; 2011 Dec; 92(6):1151-60. PubMed ID: 21691785
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity.
Magliani W; Conti S; de Bernardis F; Gerloni M; Bertolotti D; Mozzoni P; Cassone A; Polonelli L
Nat Biotechnol; 1997 Feb; 15(2):155-8. PubMed ID: 9035141
[TBL] [Abstract][Full Text] [Related]
17. A synthetic peptide as a novel anticryptococcal agent.
Cenci E; Bistoni F; Mencacci A; Perito S; Magliani W; Conti S; Polonelli L; Vecchiarelli A
Cell Microbiol; 2004 Oct; 6(10):953-61. PubMed ID: 15339270
[TBL] [Abstract][Full Text] [Related]
18. Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide.
Cenci E; Pericolini E; Mencacci A; Conti S; Magliani W; Bistoni F; Polonelli L; Vecchiarelli A
J Leukoc Biol; 2006 Jan; 79(1):40-5. PubMed ID: 16244115
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals.
Manfredi M; McCullough MJ; Conti S; Polonelli L; Vescovi P; Al-Karaawi ZM; Porter SR
Oral Microbiol Immunol; 2005 Aug; 20(4):226-32. PubMed ID: 15943767
[TBL] [Abstract][Full Text] [Related]
20. Human, monoclonal and recombinant candidacidal, pneumocysticidal and mycobactericidal antibodies.
Polonelli L
Indian J Chest Dis Allied Sci; 2000; 42(4):259-63. PubMed ID: 15597672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
